| pubmed-article:3294901 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3294901 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:3294901 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:3294901 | lifeskim:mentions | umls-concept:C0011065 | lld:lifeskim |
| pubmed-article:3294901 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:3294901 | lifeskim:mentions | umls-concept:C1527200 | lld:lifeskim |
| pubmed-article:3294901 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:3294901 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:3294901 | pubmed:dateCreated | 1987-7-10 | lld:pubmed |
| pubmed-article:3294901 | pubmed:abstractText | Administration in vivo of recombinant interleukin 2 (rIL-2) to mice induces a polyclonal IgM response. When co-administered with a specific antigen, rIL-2 can enhance concentrations of murine IgM antibodies specific for the antigen by fivefold within 7 d of initial treatment. IgM antibodies that are induced after injection of rIL-2 include antibodies specific for J5, a cell wall core lipopolysaccharide (LPS) antigen that is shared by the different members of the Enterobactericeae family. We report here that mice pretreated with rIL-2 or immunized with J5 antigen 7 d before bacterial challenge were protected from septic death that is caused by intraperitoneal challenges with Escherichia coli. Optimal protection was provided by a combined J5 antigen and rIL-2 treatment. Acquisition of the rIL-2 and J5 antigen-induced protection against lethal bacterial infection coincided temporally with maximal serum IgM titers that also contained IgM antibodies specific for the J5 antigen. In passive immunization experiments, the affinity-purified IgM fraction in sera of rIL-2-treated animals was identified as necessary and sufficient for protection. The IgM-depleted serum had no protective effect. The nonspecific augmentation of host-defense mechanisms without the induction of endotoxin manifestations makes rIL-2 a potential candidate to any alternative LPS-containing vaccines for the prevention of bacterial infections by gram-negative organisms since the core LPS antigen is shared among gram-negative bacteria. | lld:pubmed |
| pubmed-article:3294901 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3294901 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3294901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3294901 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3294901 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:3294901 | pubmed:issn | 0021-9738 | lld:pubmed |
| pubmed-article:3294901 | pubmed:author | pubmed-author:FathmanC GCG | lld:pubmed |
| pubmed-article:3294901 | pubmed:author | pubmed-author:GoronzyJJ | lld:pubmed |
| pubmed-article:3294901 | pubmed:author | pubmed-author:O'HanleyPP | lld:pubmed |
| pubmed-article:3294901 | pubmed:author | pubmed-author:WeyandCC | lld:pubmed |
| pubmed-article:3294901 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3294901 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:3294901 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3294901 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3294901 | pubmed:pagination | 1756-63 | lld:pubmed |
| pubmed-article:3294901 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:meshHeading | pubmed-meshheading:3294901-... | lld:pubmed |
| pubmed-article:3294901 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3294901 | pubmed:articleTitle | Administration in vivo of recombinant interleukin 2 protects mice against septic death. | lld:pubmed |
| pubmed-article:3294901 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3294901 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3294901 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3294901 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3294901 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3294901 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3294901 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3294901 | lld:pubmed |
